Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Belgium
Management Report
Published: January 2010
Pages: 70
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Pharmaceutical consumption in Belgium is comparatively high, although the complicated reimbursement system has hindered access to innovative drugs in the past. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. In addition to the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
WThe Belgian healthcare system is based on the principles of equitable access and freedom of choice. The majority of healthcare providers are independent practitioners who are paid on a fee-for-service basis. Health services are funded through an obligatory health insurance scheme backed up by voluntary private insurance to cover patient co-payments, which can be quite high. Management of the healthcare system in Belgium is complicated by the country’s system of multiple governments at federal, regional and community level.
Pharmaceutical consumption in Belgium is comparatively high, although the complicated reimbursement system has hindered access to innovative drugs in the past. More recently, the government has attempted to speed up regulatory procedures and improve access to new drugs of major therapeutic value.
Belgium is a relatively modest producer of pharmaceutical products, despite being a world leader in the production of vaccines. The majority of indigenous producers are small companies and only a handful of multinationals have made Belgium a key manufacturing site. Many multinationals use Belgium as an international distribution centre, meaning that import-export trade in pharmaceutical products far outweighs the value of the domestic market.
Belgium is an important base for pharmaceutical R&D and ranks second in Europe in terms of clinical trial activity. A campaign to promote Belgium as a land of investment for biopharmaceuticals has been launched by essenscia, an association representing the Belgian chemical and life science industries.
The drugs budget for 2009 was set at 3,869.9 million euros (US$5,410.1 million), 10.8% higher than in 2008. However, because the 2008 budget was exceeded, the 2009 allocation actually provided for an increase of around 3.2% over 2008 spending levels. Much of the extra funding was used to finance increased spending on innovative drugs, particularly cancer drugs, as part of the national cancer plan launched by federal Health Minister Laurette Onkelinx in 2008.
The generics market has been boosted by the loss of patent protection for high volume products such as omeprazole and simvastatin. However, moves to switch to a system of tendering for these molecules and other high volume off patent products, has called into question the future development of the generics industry.
Overall, the market is only showing modest growth as the move towards more costly innovative medicines is counterbalanced by downward pressure on prices for more mature products. Fears that Belgium’s pharmaceutical sector was starting to lose out competitively to other European countries has resulted in the setting up of a federal drugs agency, which officially started operations in 2007.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care
WThe Belgian healthcare system is based on the principles of equitable access and freedom of choice. The majority of healthcare providers are independent practitioners who are paid on a fee-for-service basis. Health services are funded through an obligatory health insurance scheme backed up by voluntary private insurance to cover patient co-payments, which can be quite high. Management of the healthcare system in Belgium is complicated by the country’s system of multiple governments at federal, regional and community level.
Pharmaceutical consumption in Belgium is comparatively high, although the complicated reimbursement system has hindered access to innovative drugs in the past. More recently, the government has attempted to speed up regulatory procedures and improve access to new drugs of major therapeutic value.
Belgium is a relatively modest producer of pharmaceutical products, despite being a world leader in the production of vaccines. The majority of indigenous producers are small companies and only a handful of multinationals have made Belgium a key manufacturing site. Many multinationals use Belgium as an international distribution centre, meaning that import-export trade in pharmaceutical products far outweighs the value of the domestic market.
Belgium is an important base for pharmaceutical R&D and ranks second in Europe in terms of clinical trial activity. A campaign to promote Belgium as a land of investment for biopharmaceuticals has been launched by essenscia, an association representing the Belgian chemical and life science industries.
The drugs budget for 2009 was set at 3,869.9 million euros (US$5,410.1 million), 10.8% higher than in 2008. However, because the 2008 budget was exceeded, the 2009 allocation actually provided for an increase of around 3.2% over 2008 spending levels. Much of the extra funding was used to finance increased spending on innovative drugs, particularly cancer drugs, as part of the national cancer plan launched by federal Health Minister Laurette Onkelinx in 2008.
The generics market has been boosted by the loss of patent protection for high volume products such as omeprazole and simvastatin. However, moves to switch to a system of tendering for these molecules and other high volume off patent products, has called into question the future development of the generics industry.
Overall, the market is only showing modest growth as the move towards more costly innovative medicines is counterbalanced by downward pressure on prices for more mature products. Fears that Belgium’s pharmaceutical sector was starting to lose out competitively to other European countries has resulted in the setting up of a federal drugs agency, which officially started operations in 2007.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care